Lewei Allison Lin1,2,3, Chad M Brummett4,5, Jennifer F Waljee4,6, Michael J Englesbe4,6, Vidhya Gunaseelan4,6, Amy S B Bohnert7,8,4. 1. Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA. leweil@med.umich.edu. 2. VA Center for Clinical Management Research (CCMR), VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. leweil@med.umich.edu. 3. Michigan Opioid Prescribing Engagement Network, Ann Arbor, MI, USA. leweil@med.umich.edu. 4. Michigan Opioid Prescribing Engagement Network, Ann Arbor, MI, USA. 5. Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA. 6. Department of Surgery, University of Michigan, Ann Arbor, MI, USA. 7. Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA. 8. VA Center for Clinical Management Research (CCMR), VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
Abstract
BACKGROUND: Prescribing naloxone to patients is a key strategy to prevent opioid overdoses, but little is known about the reach of naloxone prescribing. OBJECTIVE: Determine patient factors associated with receiving naloxone and trends over time in patients with key overdose risk factors. DESIGN: Retrospective observational study. PARTICIPANTS: Using the Clinformatics DataMart, a US-wide health insurance claims dataset, we compared adults who received opioids and naloxone (opioid+naloxone) from January 2014 to June 2017 with adults who received opioids without naloxone (opioids only), matched on gender, age ± 5 years, month/year of opioid fill, and number of opioid claims. MAIN MEASURES: Key patient-level opioid overdose risk factors included receipt of high-dosage opioids, concurrent benzodiazepines, history of opioid and other substance use disorders, and history of opioid overdose. RESULTS: We included 3963 opioid+naloxone and 19,815 opioid only patients. Key factors associated with naloxone fills included high opioid daily dosage (50 to < 90 morphine milligram equivalents (MME): AOR = 2.43, 95% CI 2.15-2.76 and ≥ 90 MME: AOR = 3.94, 95% CI 3.47-4.46; reference: < 50 MME), receiving concurrent benzodiazepines (AOR = 1.27, 95% CI 1.16-1.38), and having a diagnosis of opioid use disorder (AOR = 1.56, 95% CI 1.40-1.73). History of opioid overdose was not associated with naloxone (AOR = 0.92, 95% CI 0.74-1.15). The percent of patients receiving naloxone increased, yet less than 2% of patients in any of the key overdose risk factor groups received naloxone by the last 6 months of the study period. CONCLUSIONS: Naloxone prescribing has increased and was more likely to be co-prescribed to patients with some risk factors for overdose. However, overall prescribing remains minimal. Additional efforts are needed across health systems to increase naloxone prescribing for patients at risk for opioid overdose.
BACKGROUND: Prescribing naloxone to patients is a key strategy to prevent opioid overdoses, but little is known about the reach of naloxone prescribing. OBJECTIVE: Determine patient factors associated with receiving naloxone and trends over time in patients with key overdose risk factors. DESIGN: Retrospective observational study. PARTICIPANTS: Using the Clinformatics DataMart, a US-wide health insurance claims dataset, we compared adults who received opioids and naloxone (opioid+naloxone) from January 2014 to June 2017 with adults who received opioids without naloxone (opioids only), matched on gender, age ± 5 years, month/year of opioid fill, and number of opioid claims. MAIN MEASURES: Key patient-level opioid overdose risk factors included receipt of high-dosage opioids, concurrent benzodiazepines, history of opioid and other substance use disorders, and history of opioid overdose. RESULTS: We included 3963 opioid+naloxone and 19,815 opioid only patients. Key factors associated with naloxone fills included high opioid daily dosage (50 to < 90 morphine milligram equivalents (MME): AOR = 2.43, 95% CI 2.15-2.76 and ≥ 90 MME: AOR = 3.94, 95% CI 3.47-4.46; reference: < 50 MME), receiving concurrent benzodiazepines (AOR = 1.27, 95% CI 1.16-1.38), and having a diagnosis of opioid use disorder (AOR = 1.56, 95% CI 1.40-1.73). History of opioid overdose was not associated with naloxone (AOR = 0.92, 95% CI 0.74-1.15). The percent of patients receiving naloxone increased, yet less than 2% of patients in any of the key overdose risk factor groups received naloxone by the last 6 months of the study period. CONCLUSIONS: Naloxone prescribing has increased and was more likely to be co-prescribed to patients with some risk factors for overdose. However, overall prescribing remains minimal. Additional efforts are needed across health systems to increase naloxone prescribing for patients at risk for opioid overdose.
Entities:
Keywords:
: overdose prevention; naloxone; opioid use disorder; opioids
Authors: Patricia R Freeman; Emily R Hankosky; Michelle R Lofwall; Jeffery C Talbert Journal: Drug Alcohol Depend Date: 2018-08-30 Impact factor: 4.492
Authors: Elizabeth M Oliva; Thomas Bowe; Sara Tavakoli; Susana Martins; Eleanor T Lewis; Meenah Paik; Ilse Wiechers; Patricia Henderson; Michael Harvey; Tigran Avoundjian; Amanuel Medhanie; Jodie A Trafton Journal: Psychol Serv Date: 2017-02
Authors: Jason M Glanz; Komal J Narwaney; Shane R Mueller; Edward M Gardner; Susan L Calcaterra; Stanley Xu; Kristin Breslin; Ingrid A Binswanger Journal: J Gen Intern Med Date: 2018-01-29 Impact factor: 5.128
Authors: Gery P Guy; Kun Zhang; Michele K Bohm; Jan Losby; Brian Lewis; Randall Young; Louise B Murphy; Deborah Dowell Journal: MMWR Morb Mortal Wkly Rep Date: 2017-07-07 Impact factor: 17.586
Authors: Robin A Pollini; Susannah Slocum; Jenny E Ozga; Rebecca Joyce; Ziming Xuan; Traci C Green; Alexander Y Walley Journal: J Am Pharm Assoc (2003) Date: 2022-03-19
Authors: Mary Funke; Marcus C Kaplan; Holly Glover; Nicole Schramm-Sapyta; Andrew Muzyk; Jennifer Mando-Vandrick; Alexander Gordee; Maragatha Kuchibhatla; Emily Sterrett; Stephanie A Eucker Journal: Jt Comm J Qual Patient Saf Date: 2021-03-06
Authors: Austin S Kilaru; Manqing Liu; Ravi Gupta; Jeanmarie Perrone; M Kit Delgado; Zachary F Meisel; Margaret Lowenstein Journal: Am J Emerg Med Date: 2021-03-24 Impact factor: 4.093
Authors: Randy So; Yazid Al Hamarneh; Mark Barnes; Michael A Beazely; Michael Boivin; Julie Laroche; Harsit Patel; Aaron Sihota; Tim Smith; Ross T Tsuyuki Journal: Can Pharm J (Ott) Date: 2020-09-21